{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:38:43Z","timestamp":1792067923797,"version":"4.4.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The purpose of this review is to discuss the role of toxin inhibition in select infections and to provide recommendations for appropriate antimicrobial selection when toxin inhibition is indicated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>For select organisms, specifically Clostridioides difficile, Staphylococcus aureus, and Streptococcus pyogenes, toxin production plays an integral role in overall disease pathogenesis and progression. Some expert recommendations include utilization of an antimicrobial with toxin inhibition properties as primary or adjunctive therapy for certain infections due to these organisms, but evolving data have made the choice of antitoxin agent less clear. Clindamycin has been the long-standing standard of care agent for toxin inhibition in necrotizing S. aureus and S. pyogenes infections, but linezolid shows promise as an alternative either in the setting of drug shortages or simply when clindamycin is not optimal, while tetracyclines require further study for this indication. The role for adjunctive toxin inhibition in C. difficile infection (CDI) is less defined, as current first-line therapies already have antitoxin properties.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Toxin inhibition plays a key role in successful management of patients with infections due to toxin-producing organisms. Adjunctive therapy with a tetracycline could be considered in severe, fulminant CDI, but the associated benefit is variable. The benefit of antitoxin treatment for necrotizing S. aureus and S. pyogenes has been more consistently documented. Recent studies support linezolid as an alternative to clindamycin as an adjunctive S. aureus treatment or as monotherapy when appropriate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae251","type":"journal-article","created":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T13:42:29Z","timestamp":1725802949000},"page":"164-173","source":"Crossref","is-referenced-by-count":5,"title":["Toxin inhibition: Examining tetracyclines, clindamycin, and linezolid"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-1533","authenticated-orcid":false,"given":"Sarah B","family":"Green","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Emory University Hospital , Atlanta, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2834-3972","authenticated-orcid":false,"given":"Benjamin","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Emory University Hospital , Atlanta, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-8571","authenticated-orcid":false,"given":"Ryan","family":"Chapin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0759-8314","authenticated-orcid":false,"given":"Jillian","family":"Walters","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Johns Hopkins Bayview Medical Center , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"issue":"1","key":"2025021005562667400_CIT0001","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1086\/653116","article-title":"Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections","volume":"51","author":"Johansson","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025021005562667400_CIT0002","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/21505594.2021.1878688","article-title":"Pathogenicity and virulence of Staphylococcus aureus","volume":"12","author":"Cheung","year":"2021","journal-title":"Virulence"},{"issue":"4","key":"2025021005562667400_CIT0003","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/cid\/ciw248","article-title":"Epidemiology of invasive group A streptococcal infections in the United States, 2005-2012","volume":"63","author":"Nelson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2025021005562667400_CIT0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"2025021005562667400_CIT0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"2025021005562667400_CIT0006","doi-asserted-by":"crossref","first-page":"e4592","DOI":"10.1093\/cid\/ciaa976","article-title":"Outcomes of beta-hemolytic streptococcal necrotizing skin and soft-tissue infections and the impact of clindamycin resistance","volume":"73","author":"Horn","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025021005562667400_CIT0007","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1473-3099(20)30523-5","article-title":"Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study","volume":"21","author":"Babiker","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2025021005562667400_CIT0008","doi-asserted-by":"crossref","first-page":"ofad258","DOI":"10.1093\/ofid\/ofad258","article-title":"Clindamycin plus vancomycin versus linezolid for treatment of necrotizing soft tissue infection","volume":"10","author":"Dorazio","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"2025021005562667400_CIT0009","doi-asserted-by":"crossref","first-page":"ofad588","DOI":"10.1093\/ofid\/ofad588","article-title":"Comparison of adjuvant clindamycin vs linezolid for severe invasive group A Streptococcus skin and soft tissue infections","volume":"10","author":"Heil","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 2","key":"2025021005562667400_CIT0010","doi-asserted-by":"crossref","first-page":"ofad500.248","DOI":"10.1093\/ofid\/ofad500.248","article-title":"Clindamycin versus linezolid for group A Streptococcal bloodstream infections?: a comparative effectiveness study of adjunctive antitoxin therapy at 137 US hospitals","volume":"10","author":"Babiker","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2025021005562667400_CIT0011","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13613-018-0438-y","article-title":"Streptococcal toxic shock syndrome in the intensive care unit","volume":"8","author":"Schmitz","year":"2018","journal-title":"Ann Intensive Care"},{"key":"2025021005562667400_CIT0012","article-title":"Streptococcal superantigens: biological properties and potential role in disease","volume-title":"Streptococcus pyogenes: Basic Biology to Clinical Manifestations.","author":"Proft","year":"2016"},{"issue":"5","key":"2025021005562667400_CIT0013","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11908-010-0119-y","article-title":"Staphylococcal toxic shock syndrome: mechanisms and management","volume":"12","author":"Silversides","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"2025021005562667400_CIT0014","article-title":"Clostridia: sporeforming anaerobic bacilli","volume-title":"Medical Microbiology","author":"Wells","year":"1996","edition":"4"},{"issue":"5","key":"2025021005562667400_CIT0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/toxins8050134","article-title":"Clostridium difficile toxins a and b: insights into pathogenic properties and extraintestinal effects","volume":"8","author":"Di Bella","year":"2016","journal-title":"Toxins (Basel)"},{"issue":"6","key":"2025021005562667400_CIT0016","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/femsre\/fux048","article-title":"The role of toxins in Clostridium difficile infection","volume":"41","author":"Chandrasekaran","year":"2017","journal-title":"FEMS Microbiol Rev"},{"issue":"1","key":"2025021005562667400_CIT0017","first-page":"1","article-title":"Adjunctive protein synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections: a systematic appraisal","volume":"74","author":"Campbell","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2025021005562667400_CIT0018","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1469-0691.2007.01947.x","article-title":"Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain","volume":"14","author":"Dumitrescu","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"2025021005562667400_CIT0019","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/jac\/dkt073","article-title":"Effects of subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus","volume":"68","author":"Otto","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2025021005562667400_CIT0020","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/510396","article-title":"Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus","volume":"195","author":"Stevens","year":"2007","journal-title":"J Infect Dis"},{"issue":"5","key":"2025021005562667400_CIT0021","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1128\/AAC.47.5.1752-1755.2003","article-title":"Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release","volume":"47","author":"Coyle","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2025021005562667400_CIT0022","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/jac\/dkf192","article-title":"Virulence factor expression by gram-positive cocci exposed to subinhibitory concentrations of linezolid","volume":"50","author":"Gemmell","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2025021005562667400_CIT0023","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/AAC.49.1.88-96.2005","article-title":"Effect of antibiotics on group A streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis","volume":"49","author":"Tanaka","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2025021005562667400_CIT0024","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/AAC.00155-09","article-title":"Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus","volume":"54","author":"Smith","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2025021005562667400_CIT0025","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.47.11.3630-3633.2003","article-title":"Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines","volume":"47","author":"Krakauer","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2025021005562667400_CIT0026","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dks450","article-title":"Fidaxomicin inhibits toxin production in Clostridium difficile","volume":"68","author":"Babakhani","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2025021005562667400_CIT0027","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/jac\/dkr155","article-title":"Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model","volume":"66","author":"Baines","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2025021005562667400_CIT0028","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1348-0421.1982.tb00248.x","article-title":"Effect of clindamycin on cytotoxin production by Clostridium difficile","volume":"26","author":"Nakamura","year":"1982","journal-title":"Microbiol Immunol"},{"issue":"1","key":"2025021005562667400_CIT0029","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/dkaa386","article-title":"Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut model","volume":"76","author":"Buckley","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2025021005562667400_CIT0030","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025021005562667400_CIT0031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13017-022-00406-2","article-title":"WSES\/GAIS\/WSIS\/SIS-E\/AAST global clinical pathways for patients with skin and soft tissue infections","volume":"17","author":"Sartelli","year":"2022","journal-title":"World J Emerg Surg"},{"issue":"1","key":"2025021005562667400_CIT0032","doi-asserted-by":"crossref","first-page":"dlaa114","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"3","key":"2025021005562667400_CIT0033","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/cid\/ciu304","article-title":"Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group A streptococcal infections","volume":"59","author":"Carapetis","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025021005562667400_CIT0034","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann Med"},{"key":"2025021005562667400_CIT0035","first-page":"S0196","article-title":"Impact of doxycycline on Clostridioides difficile infection in patients hospitalized with community-acquired pneumonia","volume":"2","author":"O\u2019Leary","year":"2023","journal-title":"Am J Infect Control"},{"issue":"10","key":"2025021005562667400_CIT0036","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/jac\/dkaa289","article-title":"In vitro activity of eravacycline against common ribotypes of Clostridioides difficile","volume":"75","author":"Basseres","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2025021005562667400_CIT0037","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/10600280221089007","article-title":"Omadacycline and Clostridioides difficile: a systematic review of preclinical and clinical evidence","volume":"57","author":"Garey","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2025021005562667400_CIT0038","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijantimicag.2009.11.008","article-title":"Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole","volume":"35","author":"Lu","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2025021005562667400_CIT0039","doi-asserted-by":"crossref","first-page":"ofw094","DOI":"10.1093\/ofid\/ofw094","article-title":"Intravenous tigecycline facilitates cure of severe Clostridium difficile infection (CDI) after failure of standard therapy: a case report and literature review of tigecycline use in CDI","volume":"3","author":"Navalkele","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2025021005562667400_CIT0040","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhin.2015.11.010","article-title":"Tigecycline as last resort in severe refractory Clostridium difficile infection: a case report","volume":"92","author":"Knafl","year":"2016","journal-title":"J Hosp Infect"},{"key":"2025021005562667400_CIT0041","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijid.2014.04.025","article-title":"Tigecycline for severe Clostridium difficile infection","volume":"26","author":"Thomas","year":"2014","journal-title":"Int J Infect Dis"},{"issue":"4","key":"2025021005562667400_CIT0042","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1128\/CMR.00120-16","article-title":"The role of antibiotics in modulating virulence in Staphylococcus aureus","volume":"30","author":"Hodille","year":"2017","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2025021005562667400_CIT0043","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13054-022-03909-1","article-title":"Immunomodulation by tetracyclines in the critically Ill: an emerging treatment option","volume":"26","author":"Sauer","year":"2022","journal-title":"Crit Care"},{"issue":"4","key":"2025021005562667400_CIT0044","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.idc.2022.07.007","article-title":"ICU management of invasive beta-hemolytic streptococcal infections","volume":"36","author":"Babiker","year":"2022","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"2025021005562667400_CIT0045","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2025021005562667400_CIT0046","doi-asserted-by":"crossref","first-page":"ofad413","DOI":"10.1093\/ofid\/ofad413","article-title":"Comparison of different antibiotics and the risk for community-associated Clostridioides difficile infection: a case-control study","volume":"10","author":"Miller","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2025021005562667400_CIT0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2016.03.008","article-title":"Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis","volume":"48","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"2025021005562667400_CIT0048","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/JCM.01892-09","article-title":"Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes","volume":"48","author":"Rouzic","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"5","key":"2025021005562667400_CIT0049","doi-asserted-by":"crossref","first-page":"e6809","DOI":"10.1002\/ccr3.6809","article-title":"Catastrophic complications of PVL-MRSA necrotizing pneumonia presenting as respiratory failure and rhabdomyolysis, case report and review of the literature","volume":"11","author":"Alawad","year":"2023","journal-title":"Clin Case Rep"},{"issue":"6","key":"2025021005562667400_CIT0050","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000319557","article-title":"Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients","volume":"81","author":"Li","year":"2011","journal-title":"Respiration"},{"issue":"9","key":"2025021005562667400_CIT0051","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(21)00456-4","article-title":"Increasing clindamycin resistance in group A streptococcus","volume":"21","author":"White","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2025021005562667400_CIT0052","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"2025021005562667400_CIT0053","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2025021005562667400_CIT0054","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijantimicag.2012.01.005","article-title":"Potential protective role of linezolid against Clostridium difficile infection","volume":"39","author":"Valerio","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"2025021005562667400_CIT0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/jac\/dkg113","article-title":"In vitro activity of linezolid against Clostridium difficile","volume":"51","author":"Ackermann","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2025021005562667400_CIT0056","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/AAC.46.5.1617-1618.2002","article-title":"In vitro activity of linezolid against Clostridium difficile","volume":"46","author":"Pel\u00e1ez","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2025021005562667400_CIT0057","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1378\/chest.128.4.2732","article-title":"Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production","volume":"128","author":"Micek","year":"2005","journal-title":"Chest"},{"issue":"1","key":"2025021005562667400_CIT0058","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1378\/chest.09-1562","article-title":"Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia","volume":"138","author":"Lobo","year":"2010","journal-title":"Chest"},{"issue":"5","key":"2025021005562667400_CIT0059","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2025021005562667400_CIT0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","article-title":"Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"189","author":"Sharpe","year":"2005","journal-title":"Am J Surg"},{"issue":"6","key":"2025021005562667400_CIT0061","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2025021005562667400_CIT0062","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","article-title":"Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus","volume":"199","author":"Itani","year":"2010","journal-title":"Am J Surg"},{"issue":"3","key":"2025021005562667400_CIT0063","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/sur.2021.329","article-title":"Impact of empiric linezolid for necrotizing soft tissue infections on duration of methicillin-resistant Staphylococcus aureus-active therapy","volume":"23","author":"Lehman","year":"2022","journal-title":"Surg Infect (Larchmt)"},{"key":"2025021005562667400_CIT0064","first-page":"5720708","article-title":"Successful treatment of necrotizing fasciitis and streptococcal toxic shock syndrome with the addition of linezolid","volume":"2017","author":"Rac","year":"2017","journal-title":"Case Rep Infect Dis"},{"issue":"8","key":"2025021005562667400_CIT0065","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/ciad357","article-title":"Antibiotic myths for the infectious diseases clinician","volume":"77","author":"McCreary","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae251\/59038362\/zxae251.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/4\/164\/59038362\/zxae251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/4\/164\/59038362\/zxae251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:56:52Z","timestamp":1739167012000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/4\/164\/7750730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":65,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,9,8]]},"published-print":{"date-parts":[[2025,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae251","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2024,9,8]]}}}